Etravirine in CSF is highly protein bound

Etravirine concentrations in CSF in HIV-infected patients

(2012) J. M. Tiraboschi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

(2012) D. Croteau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

(2010) Christine Katlama et al.   ANTIVIRAL THERAPY

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

(2010) Thomas N. Kakuda et al.   CLINICAL PHARMACOKINETICS

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

(2009) Christina M Marra et al.   AIDS

Efficacy of Etravirine for Treatment of Acute HIV Meningoencephalitis

(2009) Carine Couzigou et al.   CLINICAL INFECTIOUS DISEASES

Lopinavir protein binding in HIV-1-infected pregnant women

(2009) FT Aweeka et al.   HIV MEDICINE

Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System

(2008) Scott Letendre   ARCHIVES OF NEUROLOGY

Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry

(2008) R. ter Heine et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS